BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2144440)

  • 1. Cathepsin D test helps identify breast cancers likely to recur.
    Oncology (Williston Park); 1990 Mar; 4(3):109. PubMed ID: 2144440
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the risk of recurrence in breast cancer.
    Ingle JN
    N Engl J Med; 1990 Feb; 322(5):329-31. PubMed ID: 2296275
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytosol cathepsin D in Thai women with breast cancer.
    Chearskul S; Bhothisuwan K; Tunsuphasiri V; Churinthrapun M; Keyanond V; Ornrheabroi S
    J Med Assoc Thai; 1996 Oct; 79(10):654-60. PubMed ID: 8997001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cathepsin D: an independent prognostic factor in cancer of the breast].
    Romain S; Muracciole X; Varette I; Bressac C; Brandone H; Martin PM
    Bull Cancer; 1990; 77(5):439-47. PubMed ID: 2400813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
    Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
    Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
    Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
    Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cathepsin D as a prognostic marker in breast cancer].
    Asculai E; Gopas J; Cohen Y
    Harefuah; 1996 Jun; 130(11):787-90. PubMed ID: 8794687
    [No Abstract]   [Full Text] [Related]  

  • 8. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
    Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
    Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results].
    Göhring UJ; Ingenhorst A; Crombach G; Scharl A
    Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cathepsin D in diagnosis of neoplastic diseases].
    Warwas M; Taurowska E
    Postepy Hig Med Dosw; 1993; 47(4):277-88. PubMed ID: 8309853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
    Bussen S; Rempen A; Caffier H
    Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
    Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
    Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
    Rochefort H
    C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.
    Hähnel R; Harvey J; Robbins P; Sterrett G
    Anticancer Res; 1993; 13(6A):2131-5. PubMed ID: 8297125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
    Bedner E; Harezga B; Osborn M; Domagała W
    Pol J Pathol; 1995; 46(1):11-5. PubMed ID: 7780691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between mannose-6-phosphate/IGFII receptor and cathepsin D RNA levels by in situ hybridization in benign and malignant mammary tumors.
    Zhao Y; Escot C; Maudelonde T; Puech C; Rouanet P; Rochefort H
    Cancer Res; 1993 Jun; 53(12):2901-5. PubMed ID: 7684951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squamous cell carcinoma of the vulva. Expression of tumor proteases cathepsin-D and pro-cathepsin-L.
    Hantschmann P; Beysiegel S; Kurzl R
    J Reprod Med; 1998 Nov; 43(11):933-42. PubMed ID: 9839260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
    Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
    Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.